All lobbying filings

TIBER CREEK GROUP

Lobbying for JAZZ PHARMACEUTICALS · â€‹Biopharmaceutical company.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 18, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Lobbying activity 3

Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.

Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

Budget/Appropriations

Issues related to FDA enforcement of non-FDA approved, cannabis derived CBD products in H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to the Ag/FDA amendment - technical correction to hemp in H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to intoxicating hemp products.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.